

***NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR DISSEMINATION IN THE UNITED STATES***



Abba Medix Corp. Announces Partner Portfolio Strategy and Introduction of New Product Strains and Formats for Immediate Sale

Toronto – May 21, 2020 (CNW) - Canada House Wellness Group Inc. (CSE: CHV) (“**Canada House**” or the “**Company**”), a fully integrated medical cannabis company, is pleased to announce that its wholly owned subsidiary, Abba Medix Corp. (“**Abba**”), has introduced Flyte vape pens for immediate sale to registered medical patients, including Veterans. The 0.5 gram rechargeable pens with wickless ceramic core cartridges are well-known to experienced cannabis consumers and are valued for their portability, design and rapid onset of delivery.

The new products will initially be available for sale in Sour Diesel, Pineapple Express, Green Crack God, and Granddaddy Purp strains on Thursday May 21, 2020 to registered Abba patients at www.abbamedix.com. Profiles for the new products and strains can be found under the “Products” tab on Abba’s website.

Abba is delivering on its commitment of offering a well-rounded and curated assortment of its own and third-party LP products to its medical patient base. Abba is working closely with Canada House’s wholly owned subsidiary, Canada House Clinics (“**CHC**”), to design a portfolio of products best suited to manage PTSD, pain, and other complex health conditions common to veterans. CHC’s patients currently purchase in excess of \$25M of legal cannabis per year, with the majority of those purchases coming from Veterans. At the outset these vape pens will be available for purchase by patients registered with Abba and living in Alberta, Ontario, Nova Scotia and New Brunswick. Products offerings are expected to expand nationwide during the course of this calendar year.

“As a Veteran first LP, we are excited to announce the next phase of product offerings to our important patients, particularly military veterans, who form the foundation of our company,” says Canada House CEO Chris Churchill-Smith. “We are delivering on our strategy of offering a full suite of cannabis flower and concentrate products and look forward to upcoming releases of additional formats in the very near future”.

About Canada House Wellness Group Inc.

Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.

Canada House Wellness Group’s goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally. Please visit www.canadahouse.ca or the Company’s public filings at www.sedar.com.

For further information, please contact:

Steven Pearce, Vice-President, Legal

Canada House Wellness Group

Inc. 289-980-3584

spearce@canadahouse.ca

Cautionary Statement Regarding Forward-Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis and cannabis based edibles, vapes and oils legal for recreational use on October 17, 2018 and October 17, 2019; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any

of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.